Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Hydrochloride, Methoxamine
2. Methoxamedrin
3. Methoxamine
4. Metoxamine Wellcome
5. Vasoxin
6. Vasoxine
7. Vasoxyl
8. Vasylox
9. Wellcome, Metoxamine
1. 61-16-5
2. Methoxamine Hcl
3. Methoxaminehydrochloride
4. 2-amino-1-(2,5-dimethoxyphenyl)propan-1-ol Hydrochloride
5. Mls000069686
6. 2-amino-1-(2,5-dimethoxyphenyl)propan-1-ol;hydrochloride
7. Methoxamini Hydrochloridum
8. Nsc-757102
9. Ncgc00094108-02
10. Smr000058479
11. 2-amino-1-(2,5-dimethoxyphenyl)propan-1-ol,hydrochloride
12. Methoxamine Hydrochloride (jan)
13. Sr-01000000198
14. Vasoxine Hcl
15. Prestwick_866
16. Vasoxyl (tn)
17. Methoxaminhydrochlorid
18. Vasoxine Hydrochloride
19. Methoxamine Hydrochlorid
20. Opera_id_389
21. Cas-61-16-5
22. Dsstox_cid_25782
23. Dsstox_rid_81124
24. Dsstox_gsid_45782
25. Mls001074122
26. Mls002222272
27. Schembl146117
28. Spectrum1500399
29. Chebi:6840
30. Chembl1201103
31. Hms1569l11
32. Hms1920n03
33. Pharmakon1600-01500399
34. Bcp19863
35. Tox21_111248
36. Tox21_500769
37. Ccg-38999
38. Nsc757102
39. Akos017343946
40. Lp00769
41. Ncgc00094108-01
42. Ncgc00094108-03
43. Ncgc00094108-04
44. Ncgc00094108-05
45. Ncgc00261454-01
46. Db-053802
47. Eu-0100769
48. Ft-0603257
49. Sw196992-3
50. D01020
51. M 6524
52. 058m607
53. A833069
54. Sr-01000000198-2
55. Sr-01000000198-6
56. Q26840987
57. Z2756841808
58. 2-amino-1-(2,5-dimethoxyphenyl)-propan-1-ol-hydrochlorid
59. 2-amino-1-(2,5-dimethoxyphenyl)propan-1-ol;hydron;chloride
60. Alpha-(1-aminoethyl)-2,5-dimethoxybenzenemethanol Hydrochloride (1:1)
61. Methoxamine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
| Molecular Weight | 247.72 g/mol |
|---|---|
| Molecular Formula | C11H18ClNO3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 4 |
| Exact Mass | 247.0975211 g/mol |
| Monoisotopic Mass | 247.0975211 g/mol |
| Topological Polar Surface Area | 64.7 Ų |
| Heavy Atom Count | 16 |
| Formal Charge | 0 |
| Complexity | 189 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 2 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Adrenergic alpha-Agonists; Sympathomimetics; Vasoconstrictor Agents
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
Methoxamine may be used intravenously in the treatment of hypotensive states or to relieve attacks of paroxysmal atrial tachycardia, particularly those associated with hypotension. /Methoxamine/
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 216
METHOXAMINE ... DOES NOT INCREASE VENTRICULAR RATE IN PATIENTS WITH HEART BLOCK. REFLEX BRADYCARDIA IS PROMINENT, &, THEREFORE, THE DRUG IS USED CLINICALLY TO RELIEVE ATTACKS OF PAROXYSMAL ATRIAL TACHYCARDIA. /METHOXAMINE/
Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 166
THE DRUG IS USEFUL FOR THE TREATMENT OF HYPOTENSIVE STATES WHEN IT IS DESIRED TO RAISE BLOOD PRESSURE WITHOUT CARDIAC STIMULATION. HOWEVER, METHOXAMINE HAS VERY LITTLE EFFECT ON THE CAPACITANCE VEINS, SO THAT ITS USEFULNESS IS COMPROMISED, ESPECIALLY IN TREATMENT OF VARIOUS KINDS OF SHOCK.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 817
For more Therapeutic Uses (Complete) data for METHOXAMINE HYDROCHLORIDE (9 total), please visit the HSDB record page.
Methoxamine should be used with caution in patients with hyperthyroidism, bradycardia, partial heart block, myocardial disease, or severe arteriosclerosis. Caution should be used to avoid overdosage of methoxamine, since it may cause undesirable hypertension and/or bradycardia.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 1999. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1999 (Plus Supplements)., p. 1129
Methoxamine can cause ventricular ectopic beats or severe bradycardia and decreased cardiac output. Decreased cardiac output may be especially harmful to geriatric patients and/or those with preexisting poor cerebral or coronary circulation. Bradycardia may be treated by administration of atropine. Methoxamine also increases cardiac work by increasing peripheral arterial resistance and may induce or exacerbate heart failure associated with a decreased myocardium. Some clinicians believe that the drug is contraindicated in shock caused by myocardial infarction. Large doses of methoxamine, especially if administered following repeated injections of the drug, may cause cardiac depression and a fall in blood pressure.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 1999. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1999 (Plus Supplements)., p. 1129
Methoxamine can cause severe peripheral and visceral vasoconstriction, reduced blood blow to vital organs, and decreased renal perfusion; reductions in glomerular filtration rate, urine output, and sodium excretion may occur as well as metabolic acidosis. These effects may be most likely to occur in hypovolemic patients. In addition, prolonged use of the drug may result in plasma volume depletion which may result in perpetuation of the shock state or the recurrence of hypotension when methoxamine is discontinued.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 1999. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1999 (Plus Supplements)., p. 1128
Methoxamine may cause restlessness, anxiety, nervousness, weakness, dizziness, precordial pain, tremor, respiratory distress, sweating, or pallor. Occasionally, injections of the drug may be followed by paresthesia in the extremities or feeling of coldness. A desire to void, a pilomotor response, and/or nausea and vomiting (often projectile) may also occur, especially with high doses. In addition, large doses of methoxamine may cause severe prolonged hypertension and severe headaches. Seizures and cerebral hemorrhage may result.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 1999. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1999 (Plus Supplements)., p. 1128
For more Drug Warnings (Complete) data for METHOXAMINE HYDROCHLORIDE (8 total), please visit the HSDB record page.
Adrenergic alpha-1 Receptor Agonists
Compounds that bind to and activate ADRENERGIC ALPHA-1 RECEPTORS. (See all compounds classified as Adrenergic alpha-1 Receptor Agonists.)
Sympathomimetics
Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)
Vasoconstrictor Agents
Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)
ITS PHARMACOLOGICAL PROPERTIES ARE ALMOST EXCLUSIVELY THOSE CHARACTERISTIC OF ALPHA-RECEPTOR STIMULATION, SINCE IT ACTS DIRECTLY AT THESE SITES. ... THE OUTSTANDING EFFECT IS AN INCREASE IN BLOOD PRESSURE DUE ENTIRELY TO VASOCONSTRICTION.
Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 165
METHOXAMINE, GIVEN INTRAVENOUSLY OR INTRAMUSCULARLY IN MAN, CAUSES A RISE IN SYSTOLIC & DIASTOLIC BLOOD PRESSURES THAT PERSISTS FOR 60 TO 90 MINUTES. THE PRESSOR EFFECT IS DUE ALMOST EXCLUSIVELY TO AN INCREASE IN PERIPHERAL RESISTANCE. CARDIAC OUTPUT IS DECREASED OR UNCHANGED. /METHOXAMINE/
Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 165
METHOXAMINE HAS A RELATIVELY SELECTIVE ACTION ON POSTSYNAPTIC COMPARED WITH PRESYNAPTIC RECEPTOR OF PULMONARY ARTERY; BOTH SYSTEMS WERE OF SIMILAR SENSITIVITY TO NOREPINEPHRINE & EPINEPHRINE.
BEVAN JA; ON THE SUBCLASSIFICATION OF ALPHA-ADRENERGIC RECEPTORS; VASC NEUROEFF MECH, (PROC SYMP VASC NEUROEFF MECH); 251 (1980)
TRITIUM-LABELED METHOXAMINE CROSSED THE BLOOD-BRAIN BARRIER IN RAT. THUS METHOXAMINE IS CENTRALLY ACTIVE ALPHA-ADRENERGIC AGONIST & CONCEPT THAT HYPOTHALAMIC ADRENERGIC MECHANISMS ARE INVOLVED IN ELECTROENCEPHALOGIC & BEHAVIORAL AROUSAL IS SUPPORTED.
PICKWORTH ET AL; EXP NEUROL 57(3) 1011 (1977)
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
